Brief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
30/09/2026 12:02
BRIEF-Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026 Sept 30 (Reuters) - Jade Biosciences, Inc. JBIO.O:
JADE BIOSCIENCES ANNOUNCES PRECLINICAL DATA CHARACTERIZING JADE301, A POTENTIALLY BEST-IN-CLASS, HALF-LIFE-EXTENDED ANTI-IFN-Β MONOCLONAL ANTIBODY IN DEVELOPMENT FOR DERMATOMYOSITIS, AT EADV 2026
JADE BIOSCIENCES, - JADE301 DEMONSTRATES HIGH-AFFINITY, SELECTIVE IFN-Β BINDING AND GREATER POTENCY THAN DAZUKIBART
JADE BIOSCIENCES, - JADE301 SHOWS ABOUT 25-DAY HALF-LIFE AND PREDICTABLE MUSCLE DISTRIBUTION IN PRIMATES
JADE BIOSCIENCES, - PHASE 1 TRIAL FOR JADE301 TO BEGIN IN Q4 2026; INTERIM DATA IN H2 2027
JADE BIOSCIENCES, - JADE301 WELL TOLERATED IN NON-HUMAN PRIMATES AT ALL SUBCUTANEOUS DOSES
Source text: ID:nGNX37Tkyb
Further company coverage: JBIO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million